Artrya (ASX: AYA) shares rise 3.3% as A$74m cash backs US Salix commercial rollout

Artrya Limited (ASX: AYA) shares gained 3.3% on September 1 after the medical-imaging software company outlined its transition into commercial deployment of the Salix coronary-artery-disease platform in the United States. Artrya finished the session at A$4.38 from A$4.24 on August 31, after trading between A$4.11 and A$4.42. Volume reached approximately 869,000 shares.

The financial result remains characteristic of an early commercial-stage medical technology company. FY26 statutory revenue was only A$28,000, unchanged from FY25, while operating EBITDA loss widened to A$18.99 million from A$13.29 million and net loss after tax increased to A$25.18 million from A$16.41 million. Artrya nevertheless ended June with A$74 million in cash and investments, no debt and three multi-year commercial health-system customers after completing an A$80 million capital raising during the year.

The stock’s positive September 1 reaction also followed significant weakness immediately before the results. AYA fell 10.7% on August 31 to A$4.24 after closing at A$4.75 on August 28. Even after the 3.3% recovery following the FY26 update, the A$4.38 September 1 close remained about 7.8% below the August 28 level.

Why does Artrya report only A$28,000 of statutory revenue despite starting US commercial sales?

Artrya reported underlying revenue of approximately A$177,000 before a A$149,000 non-cash accounting adjustment connected with foundation-partner option vesting, leaving A$28,000 as statutory FY26 revenue. The figure therefore understates the gross amount of initial commercial revenue recognised before that accounting adjustment but correctly represents the company’s reported IFRS revenue.

The more important operating development is that Artrya has crossed from product validation into customer billing. Tanner Health is operating under a five-year commercial agreement across five hospitals and is already live and generating Salix Coronary Plaque revenue. Northeast Georgia Health System has a three-year contract and went clinically live during July 2026, while Cone Health has a five-year agreement and is undergoing integration. Full deployment across the three foundation customers is expected during the second quarter of FY27.

That commercial progression matters more than the A$28,000 statutory number because FY26 contained only the very beginning of monetisation. However, investors should avoid confusing signed multi-year contracts with a disclosed contracted-revenue backlog. Artrya has not published total minimum revenue values for the three agreements, so their economic importance will depend on subscriptions, scan volumes and per-scan revenue as adoption grows.

Why did Artrya’s FY26 loss widen by more than 50%?

Net loss increased by approximately 53% to A$25.18 million, while operating EBITDA loss widened around 43% to A$18.99 million. Artrya attributed the higher cost base to building its United States commercial organisation and completing product-development and regulatory work, with employee benefits reaching A$10.86 million and contractor and consultant spending increasing to A$8.57 million.

The result also included a A$5.95 million non-cash expense associated with affiliate options that vested when foundation partners converted to commercial customers. That accounting charge increases the statutory loss without creating an equivalent cash outflow during FY26, making the operating EBITDA loss a useful additional measure when assessing the ongoing cost base.

Artrya’s economics therefore remain heavily front-loaded toward investment. It is building clinical integrations, regulatory submissions, United States sales infrastructure and evidence-generation programs before revenue reaches material scale. That model can produce substantial operating leverage if health-system adoption grows because software revenue can expand without replicating all development costs, but the company has not yet reached the revenue level required to demonstrate that leverage.

How much protection does A$74 million of cash give Artrya while Salix scales?

Artrya held A$44 million of cash and cash equivalents plus A$30.1 million of term deposits at June 30, producing the A$74 million total liquidity figure highlighted by management. The company carried no debt and reported net assets of A$78.3 million, compared with A$21.3 million a year earlier following the A$80 million equity financing completed during FY26.

The A$74 million position is roughly 3.9 times the FY26 operating EBITDA loss of A$18.99 million. That ratio should not be interpreted as a four-year cash runway because future working capital, product investment, capital expenditure, interest income and commercial revenue will all alter actual cash consumption. It does show that Artrya has substantially more financing capacity than its current annual operating loss would otherwise imply.

That liquidity reduces near-term pressure to fund the United States rollout through another large equity issue. The strategic burden therefore moves toward commercial execution: management has already secured the balance sheet needed to pursue growth, so investors can increasingly judge progress by the number of live hospitals, scan volume, additional contracts and revenue conversion.

Why is FDA clearance for Salix Coronary Flow potentially important for FY27 revenue?

The Salix platform currently includes FDA-cleared Coronary Anatomy and Coronary Plaque modules, while Salix Coronary Flow remains under development and regulatory review planning. Artrya is targeting United States Food and Drug Administration clearance for Coronary Flow by the end of calendar 2026.

The company identifies hospital-side CPT reimbursement of US$325 for Anatomy, US$950 for Plaque and US$877 for Coronary Flow. Those figures are not Artrya revenue. Hospitals receive the relevant reimbursement, while Artrya earns through subscription arrangements and contracted per-scan economics, making scan volumes and commercial terms more important than simply multiplying reimbursement values by patient numbers.

Adding Coronary Flow would nevertheless broaden the economic opportunity at existing customer sites because the platform could address anatomy, plaque and physiological flow analysis inside one workflow. Artrya says Salix is designed to produce analysis in under ten minutes at the point of care, compared with workflows where externally processed analyses can introduce longer turnaround times.

Could the SAPPHIRE study become more important commercially than Artrya’s first three customers?

SAPPHIRE involves six major United States health systems: Mass General Brigham, Piedmont Healthcare, HCA Healthcare, Dignity Health within CommonSpirit, Ascension and Huntsville Hospital Health System. The retrospective study is designed to validate Artrya’s Plaque Dispersion Score, including its ability to identify coronary-artery-disease risk among women.

Management is explicitly treating those institutions as part of the future commercial funnel rather than viewing the research program solely as clinical validation. Converting even a portion of participating health systems into paying customers would significantly broaden the current three-customer base, although participation in SAPPHIRE creates no obligation for an institution to purchase Salix.

That distinction is central to Artrya’s approximately A$691 million market capitalisation at the September 1 close. The valuation is many times larger than current revenue and therefore reflects expectations that clinical adoption eventually becomes repeatable commercial deployment.

FY27 will provide the first meaningful test. Tanner is already producing revenue, Northeast Georgia Health System has gone live, Cone Health is integrating and the SAPPHIRE network offers additional potential customers. A$74 million of liquidity gives Artrya time to execute; what the market now needs is evidence that signed sites translate into a rapidly rising revenue line before the current cost base consumes too much of that financial advantage.